Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL599790 | 1.00 | FFAR3 (0.46) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Proline SCHEMBL8462550 | 0.89 | MEN1 (0.44) | PRCPMEN1BLMKMT2ADPP4 | |
| Succinic Acid SCHEMBL8462554 | 0.89 | MEN1 (0.44) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL8555781 | 0.87 | PRCP (0.46) | FFAR3PRCPDPP7MEN1BLM | |
| Dodecanoate SCHEMBL17223917 | 0.87 | PRCP (0.56) | PRCPMEN1KMT2ATLR2 | |
| Decanoic Acid SCHEMBL13279505 | 0.87 | PRCP (0.56) | PRCPMEN1KMT2ATLR2 | |
| Dodecanoate SCHEMBL17223919 | 0.87 | PRCP (0.56) | PRCPMEN1KMT2ATLR2 | |
| Proline SCHEMBL14976459 | 0.85 | PRCP (0.49) | PRCPDPP7MEN1BLMKMT2A | |
| Proline SCHEMBL27639357 | 0.85 | PRCP (0.47) | PRCPDPP7MEN1BLMKMT2A | |
| Proline SCHEMBL28067798 | 0.85 | PRCP (0.47) | PRCPDPP7MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948199-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LAB INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1960415-B1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LAB INC (US) | 2015-03-04 | — | — | EP | disclosed |
| CN-102534864-B | Preparation method of alkylation chitosan fiber | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2013-10-16 | — | — | CN | disclosed |
| US-8293253-B2 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| CN-102534864-A | Preparation method of alkylation chitosan fiber | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2012-07-04 | — | — | CN | disclosed |
| US-8114440-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8017159-B2 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | IDEXX LABORATORIES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7754679-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1960415-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX Laboratories Inc (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1948199-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX Laboratories Inc (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1804771-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007058800-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058801-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2006050002-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | LIPA, CEL, LPXN | FFAR3 1167/4885HDAC3 161/4885HDAC1 476/4885 |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | PHOSPHO1, SGMS1, PCYT1A | FFAR3 1077/4885HDAC3 2623/4885HDAC1 3619/4885 |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | FFAR3 1077/4885HDAC3 2623/4885HDAC1 3619/4885 |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | SLCO2A1, SLCO1A2, SLCO2B1 | FFAR3 1862/4885HDAC3 3692/4885HDAC1 3869/4885 |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | FFAR3 1077/4885HDAC3 2623/4885HDAC1 3619/4885 |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | ANXA6, ANXA2, PLTP | FFAR3 1261/4885HDAC3 3679/4885HDAC1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.